Table 2.
Identified analytes from each method of analysis. Analytes in bold were identified as validated biomarker candidates. Unless otherwise indicated, P-values were calculated with a Student’s t-test. Direction of arrows refers to protein level in patient samples compared to control samples.
| Analyte | Luminex | Myriad-RBM | 2D-DIGE | Western Blot | ||
|---|---|---|---|---|---|---|
|
| ||||||
| JNCL | all NCLs | JNCL | all NCLs | JNCL | all NCLs | |
| BDNF | ↑↑↑† | ↑↑↑† | ↑↑↑ | |||
| NrCAM | ↑† | ↑↑↑ | ↑↑ | |||
| Clusterin | ↑↑↑ | ↑↑ | ||||
| Adiponectin | ↑↑↑ | ↑ | ↑ | |||
| Apolipoprotein E | ↑ | ↑ | ↑ | |||
| VCAM-1 | N.S. | ↑ | ↑ | |||
| Myoglobin | ↑ | N.S. | ↑ | |||
| Kininogen-1 (HMW) | ↑‡ | ↑↑ | ↑ | |||
| NCAM | ↑↑↑ | ↑↑↑ | ||||
| TSH | ↑↑↑ | |||||
| Thrombopoietin | ↑↑↑ | |||||
| Apolipoprotein AIV | ↑ | ↑‡ | N.S. | N.S. | ||
| PAI-1 | ↑↑↑ | ↑↑↑ | N.S. | |||
| ICAM-1 | N.S. | N.S. | ↑↑ | |||
| CK-MB | ↑↑ | N.S. | N.S. | |||
| vWF | ↑ | N.S. | N.S. | |||
| LOX1 | ↓ | N.S. | N.S. | |||
| Complement C4/C4a | N.S. | N.S. | N.S. | ↑ | ||
| Apolipoprotein AII | ↑ | N.S. | N.S. | |||
| zinc α2-glycoprotein | ↑‡ | N.S. | ||||
| CFH | N.S. | N.S. | ↓ | |||
| CD5/CD5L | N.S. | ↑ | N.S. | N.S. | ||
| C1 inhibitor | ↓ | N.S. | ||||
| C1s | ↓ | N.S.† | ||||
↑↑↑, P < 0.0001;
↑↑, 0.0001 ≤ P ≤ 0.001;
↑, 0.002 ≤ P ≤ 0.05.
N.S., not significant.
, Mann Whitney U-test.
, P values for comparisons in males only.
Abbreviations: brain derived neurotrophic factor (BDNF), neuronal cell adhesion molecule (NrCAM), vascular cell adhesion molecule 1 (VCAM-1), high molecular weight (HMW), neural cell adhesion molecule (NCAM), thyroid stimulating hormone (TSH), platelet activating inhibitor 1 (PAI-1), immune cell adhesion molecule 1 (ICAM-1), creatine kinase MB (CK-MB), von Willebrand’s Factor (vWF), lectin-like oxidized LDL receptor 1 (LOX1), complement factor H (CFH), fatty acid binding protein (FABP)